GNH USA

USA — NDC

Emgality 120 mg/mL (Galcanezumab-Gnlm) Injection, solution

GNH USA supplies EMGALITY 120 mg/mL (Galcanezumab-Gnlm), a calcitonin gene-related peptide (CGRP) antagonist for the preventive treatment of migraine

Galcanezumab-Gnlm
Emgality
INJECTION, SOLUTION
120 mg/mL

Request sourcing

1
Pack/s

What is Galcanezumab-Gnlm?

Galcanezumab-gnlm, the active ingredient in EMGALITY 120 mg/mL, is a calcitonin gene-related peptide (CGRP) antagonist presented as a 120 mg/mL injection, solution for subcutaneous use. It is indicated for the preventive treatment of migraine and the treatment of episodic cluster headache in adults.

GNH USA supplies EMGALITY 120 mg/mL as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide.

What is Galcanezumab-Gnlm used for?

EMGALITY 120 mg/mL is a calcitonin gene-related peptide (CGRP) antagonist used in the management of migraine and cluster headaches. It is specifically designed to target and block the CGRP ligand, which plays a key role in these conditions.

- Migraine: Preventive treatment to reduce the frequency and severity of migraine attacks. - Episodic Cluster Headache: Treatment to manage and reduce the frequency of cluster headache episodes during the cluster period.

What are the side effects of Galcanezumab-Gnlm?

EMGALITY 120 mg/mL may cause various side effects, ranging from common to serious or rare.

Common Side Effects: - Injection site reactions, such as pain, redness, or swelling. - Constipation. - Nausea. - Fatigue. - Upper respiratory tract infection. - Dizziness. - Hypersensitivity reactions, including rash, itching, and urticaria.

Serious or Rare Side Effects: - Serious hypersensitivity reactions, including anaphylaxis and angioedema. - New-onset or worsening of pre-existing hypertension. - New-onset or worsening of pre-existing Raynaud's phenomenon. - Serious complications of constipation.

What precautions apply to Galcanezumab-Gnlm?

EMGALITY 120 mg/mL should be used with caution and under the supervision of a healthcare provider. Important precautions include: - Hypersensitivity: EMGALITY is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or any of the excipients. - Hypersensitivity Reactions: Discontinue administration if a serious hypersensitivity reaction occurs and initiate appropriate therapy. - Constipation: Monitor for signs of serious complications of constipation. - Hypertension: Monitor blood pressure regularly, especially in patients with pre-existing hypertension. - Raynaud's Phenomenon: Monitor for new-onset or worsening of Raynaud's phenomenon. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

What does Galcanezumab-Gnlm interact with?

EMGALITY 120 mg/mL may interact with other medications, requiring careful monitoring or avoidance.

Major Interactions (Avoid): - None identified.

Moderate Interactions (Monitor Closely): - None identified.

Frequently asked questions

What is EMGALITY 120 mg/mL used for?+
EMGALITY 120 mg/mL is used for the preventive treatment of migraine and the treatment of episodic cluster headache in adults. It works by binding to and blocking the calcitonin gene-related peptide (CGRP) ligand, which is involved in the pathogenesis of these conditions.
How does Galcanezumab-Gnlm work?+
Galcanezumab-gnlm is a humanized monoclonal antibody that specifically binds to the CGRP ligand and blocks its interaction with the receptor. By inhibiting CGRP, EMGALITY helps to prevent the onset and reduce the frequency and severity of migraine and episodic cluster headaches.
What is the usual dose of EMGALITY 120 mg/mL?+
The dosage of EMGALITY 120 mg/mL is determined by a healthcare provider based on the specific condition being treated. For migraine prevention, a loading dose of 240 mg (administered as two consecutive injections of 120 mg each) is followed by monthly doses of 120 mg. For episodic cluster headache, a 300 mg dose (administered as three consecutive injections of 100 mg each) is given at the onset of the cluster period, followed by monthly doses until the end of the cluster period.
Is EMGALITY 120 mg/mL safe during pregnancy or breastfeeding?+
The safety of EMGALITY 120 mg/mL during pregnancy or breastfeeding has not been established. It is important to consult with a healthcare provider to discuss the potential risks and benefits before using this medication during pregnancy or while breastfeeding.
How do I order EMGALITY 120 mg/mL from GNH USA?+
To order EMGALITY 120 mg/mL from GNH USA, submit an enquiry on the product page at gnh-usa.com with the required quantity. GNH USA supplies hospitals, pharmacies, and procurement teams across international markets. The team will ask you to confirm your trade or institutional credentials and will reply with pricing, availability, shipping (including cold-chain where relevant), and the import paperwork.
How does EMGALITY 120 mg/mL compare to other migraine treatments?+
EMGALITY 120 mg/mL is a CGRP antagonist specifically designed for the preventive treatment of migraine. Compared to other migraine treatments, it offers a targeted approach by blocking the CGRP ligand, which is involved in the pathogenesis of migraine. The choice of treatment depends on individual patient factors and should be discussed with a healthcare provider.
How should EMGALITY 120 mg/mL be stored and handled?+
EMGALITY 120 mg/mL should be stored refrigerated at 2-8°C (36-46°F) in the original carton to protect it from light. It should not be frozen or shaken. The medication can be stored out of refrigeration in the original carton at temperatures up to 30°C (86°F) for up to 7 days. Once stored out of refrigeration, it should not be placed back in the refrigerator. If these conditions are exceeded, the medication must be discarded.
How is EMGALITY 120 mg/mL administered?+
EMGALITY 120 mg/mL is administered subcutaneously. It can be injected into the abdomen, thigh, back of the upper arm, or buttocks. The injection should be performed by a healthcare provider or as instructed by a healthcare professional.
What are the most serious risks to watch for with EMGALITY 120 mg/mL?+
The most serious risks associated with EMGALITY 120 mg/mL include serious hypersensitivity reactions, such as anaphylaxis and angioedema, new-onset or worsening of pre-existing hypertension, and serious complications of constipation. Patients should be monitored for these risks and seek immediate medical attention if they occur.
Who should not use EMGALITY 120 mg/mL?+
EMGALITY 120 mg/mL is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or any of the excipients. Patients with a history of severe hypersensitivity reactions to this medication or its components should avoid using it. Always consult with a healthcare provider to determine if EMGALITY 120 mg/mL is appropriate for your specific condition.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Galcanezumab-Gnlm
Brand
Emgality
Strength
120 mg/mL
Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Pack size
1 SYRINGE in 1 CARTON (0002-1436-11) / 1 mL in 1 SYRINGE (0002-1436-01)
Manufacturer
Eli Lilly and Company
Origin
USA

Related products

EMGALITY 120 mg/mL

EMGALITY 120 mg/mL

Galcanezumab-Gnlm · 120 mg/mL

Emgality
INJECTION, SOLUTION
Eli Lilly and Company
USA
EMGALITY 120 mg/mL

EMGALITY 120 mg/mL

Galcanezumab-Gnlm · 120 mg/mL

Emgality
INJECTION, SOLUTION
Eli Lilly and Company
USA
EMGALITY 100 mg/mL

EMGALITY 100 mg/mL

Galcanezumab-Gnlm · 100 mg/mL

Emgality
INJECTION, SOLUTION
Eli Lilly and Company
USA